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Abstract
Background: Cocaine use is frequent in patients receiving methadone maintenance treatment (MMT) and can
jeopardize their treatment response. Identifying clinical predictors of cocaine use during methadone treatment can
potentially improve clinical management. We used longitudinal data from the ANRS Methaville trial both to
describe self-reported occasional and regular cocaine use during MMT and to identify clinical predictors.
Methods: We selected 183 patients who had data on cocaine (or crack) use at months 0 (M0), M6, and/or M12,
accounting for 483 visits. The outcome was “cocaine use” in three categories: “no,” “occasional,” and “regular” use.
To identify factors associated with the outcome over time, we performed a mixed multinomial logistic regression.
Results: Time on methadone was significantly associated with a decrease in occasional but not in regular cocaine
use from 14.7 % at M0 to 7.1 % at M12, and from 10.7 % at baseline to 6.5 % at M12, respectively. After multiple
adjustments, opiate injection, individuals screening positive for attention deficit hyperactivity disorder (ADHD)
symptoms, and those presenting depressive symptoms were more likely to regularly use cocaine.
Conclusions: Although time on MMT had a positive impact on occasional cocaine use, it had no impact on regular
cocaine use. Moreover, regular cocaine users were more likely to report opiate injection and to present ADHD and
depressive symptoms. Early screening of these disorders and prompt tailored pharmacological and behavioral
interventions can potentially reduce cocaine use and improve response to MMT.
Trial registration: The trial is registered with the French Agency of Pharmaceutical Products (AFSSAPS) under the
number 2008-A0277-48, the European Union Drug Regulating Authorities Clinical Trials, number Eudract 2008-
001338-28, the ClinicalTrials.gov Identifier: NCT00657397, and the International Standard Randomised Controlled
Trial Number Register ISRCTN31125511.
Keywords: Methadone, Opioid dependence, Cocaine, ADHD, Maintenance, Depression, Injection
* Correspondence: perrine.roux@inserm.fr
1INSERM, UMR_S 912, Sciences Economiques & Sociales de la Santé et
Traitement de l’Information Médicale (SESSTIM), 27 bd Jean Moulin, 13385
Marseille, France
2Aix Marseille Université, UMR_S 912, IRD, Marseille, France
Full list of author information is available at the end of the article
© 2016 Roux et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Roux et al. Harm Reduction Journal  (2016) 13:12 
DOI 10.1186/s12954-016-0100-7
Background
Opioid maintenance treatment (OMT), especially metha-
done maintenance treatment (MMT), is widely recognized
as a gold standard for managing opioid dependence [1].
However, many socio-economic, behavioral, and clinical
conditions and determinants may impair response to
MMT and consequently negatively impact the primary
goal of this treatment which is abstinence from street-
opioid use. Studies have pointed out that many opioid-
dependent individuals are also either cocaine-dependent
or are cocaine users [2–4] and that the effectiveness of
methadone treatment is lower in this population [5].
Moreover, no pharmacological treatment currently ex-
ists for harmful cocaine use or dependence. Treat-
ment is based on psychological intervention using
cognitive behavioral therapy (CBT) or contingency
management [6, 7].
Some studies have shown that retention in OMT has a
positive impact on cocaine use, especially in less severe
cocaine users [4, 8, 9]. However, other studies highlight
that people who continue to use cocaine while on OMT
are more likely to have a poorer response to treatment,
in terms of retention and abstinence from street-opioid
use [10, 11], and may also have a lower level of pharma-
cokinetic exposure to methadone, the consequence be-
ing a decreased effect of methadone [12]. Moreover,
studies on methadone-related mortality [13, 14] have
shown that cocaine use while on OMT is associated with
a higher risk of overdose. A recent study conducted in
San Francisco showed that more than one third of all
fatal opioid overdoses involved also cocaine [15]. As it is
known that cocaine use during methadone treatment
may be associated with premature discharge [16], it
seems important to identify predictors of cocaine use, in
order to improve clinical management of these patients.
Some hypotheses have been put forward regarding the
possible association between psychiatric comorbidi-
ties—such as depression [17], attention deficit/hyper-
activity disorder (ADHD) [18], alcohol dependence [19],
and severe opioid dependence [20]—and more severe
patterns of cocaine use [21, 22]. However, it would seem
more relevant to investigate correlates of cocaine use
more thoroughly and to provide clinicians with indica-
tions as to how they can better manage MMT patients
whose cocaine use is deemed “at-risk.” We used longitu-
dinal data from the ANRS Methaville trial, which en-
rolled opioid-dependent individuals starting methadone
maintenance, to describe the pattern of cocaine use dur-
ing MMT and to identify clinical correlates.
Methods
Study design
From January 2009 to January 2010, the ANRS Methaville
study—a multi-site, open-label, randomized, controlled,
non-inferiority trial—recruited 195 men and women in 10
sites in France. The study aimed to compare methadone
initiation in France in specialized centers (standard care)
with initiation in primary care. This study was approved
by the ethics committee for the protection of patients in
Paris, France. All individuals provided written, informed
consent before participating in the study. The full protocol
is described elsewhere [23]. Each participant was followed
up for 12 months. Medical visits, completion of self-
administered questionnaires, and phone interviews
occurred at enrolment (M0), 3, 6, and 12 months (M3,
M6, and M12, respectively).
Variables and instruments
Computerized assisted phone interviews (CATI) were
used to collect the following information at enrolment
and during follow-up visits: (1) socio-demographic char-
acteristics: age, gender, employment status, housing sta-
tus (renter or owner); (2) history of drug use: age at first
drug use, history of overdoses, history of drug injection;
(3) current drug, alcohol, and tobacco use; (4) percep-
tion of the adequacy of the prescribed methadone dose,
categorized into 3 possible answers: too high, adequate,
too low. This was done to assess each interviewee’s satis-
faction with methadone treatment.
Patients reporting that they had used cocaine or crack
use once during the previous month were considered
“occasional cocaine users,” while those reporting cocaine
(or crack) use at least twice in the previous month were
considered “regular cocaine users.”
Alcohol consumption assessment was based on the al-
cohol use disorders test (AUDIT) with a threshold of 13
indicating alcohol dependence [24], while depressive
symptoms were assessed using the Center for Epidemio-
logic Studies-Depression Scale (CES-D) with a threshold
of 17 indicating depression for males and 23 for females
[25]. The Fagerstrom Scale, comprising 6 items, evalu-
ated tobacco dependence, a threshold of 3 (on a 0 to 10
scale) defining dependence [26].
Drug use was assessed using the Opiate Treatment
Index (OTI) questionnaire, which documented the previ-
ous 3 days when drugs were used (last 3 days when
drugs were taken and amounts consumed) during the
previous month [27].
The self-administered questionnaire at M0, M6, and
M12 included two screening tools. The first was the Adult
ADHD Self-Report Scale-Version 1.1 (ASRS-V1.1) which
evaluates attention deficit hyperactivity disorder (ADHD)
in patients. The scoring algorithm used was the sum score
obtained adding up the scores (0–4) of the first 6 items
[28]. Then, we defined the diagnosis of ADHD using 14 as
a cut-off score [29]. The second tool was the Beck Hope-
lessness Scale (BHS), a 20-item self-reported inventory,
where a score of 9 or more indicates suicide risk [30].
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During medical visits, physicians collected data on
withdrawal symptoms using the Objective Opioid With-
drawal Scale (OOWS) which comprises a list of 13 with-
drawal symptoms [31].
During the phone interviews, patients were asked
about their prescribed methadone dose. At each follow-
up visit, physicians noted the methadone dose prescribed
to the patient in the medical questionnaire.
Statistical analyses
From the 195 patients included in the trial, we used data
of 183 patients (177 at baseline) who answered the OTI
section about cocaine use at least once during follow-up,
accounting for 486 visits. For these analyses, we used
only the M0, M6 and M12 visits where data for most of
the variables were available. First, we compared the indi-
vidual characteristics of the study sample between those
who consumed cocaine or crack at enrolment (i.e. before
methadone initiation) and those who did not. These
comparisons were performed using a chi-squared test
(for categorical variables) and a Wilcoxon test (for
continuous variables). To identify the factors associ-
ated with cocaine use during treatment, we used a
multinomial mixed model with a 3-category outcome:
no cocaine use (reference), occasional cocaine use,
and regular cocaine use.
We tested the following factors as possible explanatory
variables for the consumption of cocaine: (1) socio-
demographic characteristics (sex, age, employment,
housing (home owner or renter)); (2) drug use-related
factors (history of drug injection, previous drug over-
dose, opioid injection; (3) clinical factors: methadone-
associated characteristics (methadone induction arm,
methadone dose: ≥60 mg vs. <60 mg, perceiving metha-
done dose to be too low vs. adequate or too high); clin-
ical factors (depressive symptoms, risk of suicide, ADHD
symptoms, at least 1 withdrawal symptom); tobacco
dependence and alcohol dependence. We first performed
a univariate mixed multinomial logistic regression
adjusted on methadone treatment duration. A liberal p
value of <0.20 in the univariate analyses was chosen to
select eligible variables for the multivariate model. A
stepwise procedure was used to identify the best model
by removing variables one at a time based on a p value
of >0.05. All analyses were performed using the SPSS
v15.0 (SPSS, Inc, Chicago, IL) and Intercooled Stata 12
(StataCorp LP, College Station, TX) software packages
using the GLLAMM procedure for multinomial analysis.
Results
Sample description
Among the 177 patients with available data at enroll-
ment, 29 (16.4 %) were female and median [IQR] age
was 32 [27–38] years (Table 1). At the baseline visit, i.e.
before starting methadone treatment, half of the patients
(50.9 %) were employed and two thirds (62.1 %) rented
or owned their home. With respect to psychiatric co-
morbidities, at the baseline visit, 39.4 % of the patients
had depressive symptoms, 30.9 % had risk of suicide,
and 32.2 % had ADHD symptoms. Sixty-two percent of
the patients had at least one withdrawal symptom at the
baseline visit. At the baseline visit, 13.9 % reported alco-
hol dependence, half reported a history of drug injection,
and 12.4 % reported overdosing at some point in their
life. Only 1.3 % of patients received more than 60 mg of
methadone a day. Finally, 25.4 % reported cocaine use at
baseline. At baseline, patients who reported using co-
caine were significantly more likely to be unemployed,
to have depressive symptoms, a risk of suicide, a history
of drug injection and ADHD symptoms, than those who
did not use cocaine (Table 1).
Cocaine use during the first 12 months of methadone
maintenance treatment
Figure 1 shows the percentage of patients reporting co-
caine use at each visit: baseline (M0), M6, and M12. At
the baseline visit, of those patients who had data on co-
caine use (n = 177), 25.4 % reported using cocaine during
the previous month, 14.7 % occasionally and 10.7 %
regularly. The M6 visit showed a decrease in cocaine use
with only 15.6 % patients reporting they used it (8.4 %
occasionally and 7.1 % regularly) and this decrease
remained stable at M12 with 13.6 % (7.1 % occasionally
and 6.5 % regularly). Compared with enrolment there-
fore, the proportion of patients reporting cocaine use de-
creased significantly at the M6 and M12 visits (Table 2).
Among the 45 cocaine users at baseline, 8 were lost to
follow-up, 10 continued to use cocaine, and 27 stopped
using it.
Factors associated with occasional cocaine use
Univariate analysis (Table 2) highlighted the eligibility of
several variables for the multivariate model (p < 0.20).
First, no socio-demographic variable was associated with
occasional cocaine use. A history of drug injection,
current opioid injection, depressive symptoms, and alco-
hol dependence were considered eligible variables to ex-
plain occasional cocaine use. A significant decrease in
occasional cocaine use was observed as the duration of
methadone treatment increased.
After multivariate analysis (Table 3), two variables
remained positively associated with the outcome: a lon-
ger duration on methadone treatment (at the M12 visit
only) was associated with less occasional cocaine use
and current opioid injection was associated with higher
risk of being occasional cocaine user. Those who had
depressive symptoms were slightly more likely to be oc-
casional cocaine users.
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Table 1 Description of the sample: socio-demographic and behavioral characteristics at baseline
No cocaine use
(n = 132)
Occasional cocaine use
(n = 26)
Regular cocaine use
(n = 19)
Total
(n = 177)
p valuea
Gender, n (%)
Male 110 (83.33) 23 (88.46) 15 (78.95) 148 (83.62) 0.70
Female 22 (16.67) 3 (17.54) 4 (21.05) 29 (16.38)
Methadone induction arm
Specialized centers 31 (23.5) 7 (26.9) 4 (21.1) 42 (23.7) 0.89
Primary care 101 (76.5) 19 (73.1) 15 (78.9) 135 (76.3)
Ageb, median (IQR) 32 (27–38) 30 (27–37) 32 (27–40) 32 (27–38) 0.77
Employed, n (%)
No 55 (44.35) 15 (57.69) 13 (68.42) 83 (49.11) 0.09
Yes 69 (55.65) 11 (42.31) 6 (31.58) 86 (50.89)
Home owner or renter, n (%)
No 43 (34.68) 10 (38.46) 11 (57.89) 64 (37.87) 0.15
Yes 81 (65.32) 16 (61.54) 8 (42.11) 105 (62.13)
Depressive symptoms, n (%)c
No 80 (66.67) 12 (46.15) 8 (42.11) 100 (60.61) 0.03
Yes 40 (33.33) 14 (53.85) 11 (57.89) 65 (39.39)
Risk of suicide, n (%)d
No 79 (73.15) 16 (69.57) 8 (44.44) 103 (69.13) 0.05
Yes 29 (26.85) 7 (30.43) 10 (55.56) 46 (30.87)
ADHD symptoms, n (%)
No 76 (70.37) 17 (73.91) 8 (44.44) 101 (67.79) 0.07
Yes 32 (29.63) 6 (26.09) 10 (55.56) 48 (32.21)
Previous drug overdose, n (%)
No 117 (88.64) 22 (84.62) 16 (84.21) 155 (87.57) 0.64
Yes 15 (11.36) 4 (15.38) 3 (15.79) 22 (12.43)
History of drug injection, n (%)
No 66 (53.66) 12 (46.15) 5 (26.32) 83 (49.40) 0.08
Yes 57 (46.34) 14 (53.85) 14 (73.68) 85 (50.60)
Age at first drug use, median (IQR)b 18 (17–22) 18 (16–21) 18 (17–19) 18 (17–21) 0.23
At least one withdrawal symptom, n (%)
No 49 (42.24) 6 (25.00) 5 (26.32) 60 (37.74) 0.16
Yes 67 (57.76) 18 (75.00) 14 (73.68) 99 (62.26)
Methadone dose >60 mg, n (%)
No 110 (99.10) 20 (100.00) 17 (94.44) 147 (98.66) 0.25
Yes 1 (0.90) 0 1 (5.6) 2 (1.34)
Alcohol dependence, n (%)a,e
No 108 (88.52) 21 (84.00) 14 (73.68) 143 (86.14) 0.21
Yes 14 (11.48) 4 (16.00) 5 (26.32) 23 (13.86)
aChi-squared or exact Fisher test/Kruskal–Wallis
bIn years
cCES-D score >17 for males and >23 for females
dBeck ≥9
eAUDIT score ≥13
Roux et al. Harm Reduction Journal  (2016) 13:12 Page 4 of 10
Factors associated with regular cocaine use
For regular cocaine use, univariate analysis highlighted
the same variables as those for occasional cocaine use.
However, additional variables were associated with regu-
lar cocaine use. With respect to socio-demographic vari-
ables, regular cocaine users were less likely to be owners
or renters of their house and to be employed. In
addition, perceiving methadone dose as too low, suicidal
risk and ADHD symptoms were also eligible to enter the
multivariate model. After the latter was analyzed, three
variables remained associated with regular cocaine use:
depressive symptoms, ADHD symptoms and current
opioid injection. It is worth noting that time on metha-
done was not associated with a reduction in regular
cocaine use.
The methadone induction arm (specialized center
versus primary care) was not associated with either
occasional or regular cocaine use.
Discussion
Our results showed that cocaine use was highly prevalent
among opioid-dependent individuals initiating methadone
maintenance treatment, with almost one third of the sam-
ple reporting it at baseline. Furthermore, depressive symp-
toms, ADHD disorders, and current opioid injection were
the main predictors of regular cocaine use. These results
may have important repercussions on clinical manage-
ment of these patients.
Our results about cocaine use prevalence are in line
with other studies where 30 to 50 % of opioid-
dependent individuals seeking care for opioid depend-
ence used cocaine concomitantly [32–34]. More
specifically, in our study, at baseline, 14.7 and 10.7 %
of the study sample were occasional and regular
cocaine users, respectively. This is in line with other
findings [35].
Cocaine use decreased during the 12-month metha-
done maintenance treatment (MMT) follow-up, with 27
(15 %) patients stopping use altogether. This result cor-
roborates findings in other studies [9, 36] and suggests
that despite treatment, certain cocaine users do not re-
duce their cocaine consumption. In turn, this may act as
a barrier to MMT optimization. Accordingly, these vul-
nerable patients deserve special investigation, particu-
larly those who continue to use cocaine regularly.
To better understand patterns of cocaine use in MMT
patients, we separated occasional users from regular
users at all visits and studied the factors associated with
occasional and regular cocaine use over 12 months of
follow-up. Univariate analyses revealed that patients with
the most severe characteristics, that is to say, users with
a longer history of drug use, those with a history of
injecting practices and polydrug users, were more likely
to use cocaine during MMT.
One of the main results from the present study is that
ADHD was associated with regular cocaine use. It is
known that ADHD is a common psychiatric comorbidity
among cocaine-dependent patients [37], as cocaine may
be used as a means of self-medication for the disease
[38]. Furthermore, it is well known that substance use
and ADHD are closely correlated [39]. Consequently,
screening for ADHD at methadone initiation and appro-
priate clinical management during methadone treat-
ment, together with the monitoring of cocaine use, can
potentially help patients to improve their response and
reduce overdose risks [13, 14]. Few clinical responses
currently exist for cocaine dependence [40] and cocaine
use during MMT [41–43]. Standard treatment includes
Fig. 1 Cocaine use in methadone patients: M0, M6, and M12 visits
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Table 2 Factors associated with cocaine use: logistic mixed model adjusted for follow-up visit
Occasional cocaine use vs no use Regular cocaine use vs no use
Number of visits (%) or median (IQR) Number of patients OR [95 % CI] p OR [95 % CI] p
Follow-up
M0 177 (36.4) 177 (96.7) 1 1
M6 155 (31.9) 155 (84.7) 0.35 (0.15–0.82) 0.02 0.41 (0.16–1.01) 0.05
M12 154 (31.7) 154 (84.2) 0.28 (0.12–0.69) 0.01 0.35 (0.14–0.90) 0.03
Methadone induction arm
Specialized centers 130 (20.5) 43 (23.4) 1 1
Primary care 503 (79.5) 141 (76.6) 0.87 (0.28–2.69) 0.80 1.28 (0.37–4.40) 0.70
Gender
Male 411 (84.6) 154 (84.2) 1 1
Female 75 (15.4) 29 (15.8) 0.49 (0.12–2.10) 0.33 1.10 (0.29–4.23) 0.89
Agea 32 (27–39) 0.89 (0.46–1.73) 0.74 1.03 (0.52–2.02) 0.94
Employed
No 131 (41.7) 99 (56.9) 1
Yes 183 (58.3) 122 (70.1) 1.02 (0.43–2.39) 0.97 0.52 (0.21–1.30) 0.16
Home owner or renter
No 107 (34.1) 76 (43.7) 1 1
Yes 207 (65.9) 128 (73.6) 0.77 (0.31–1.92) 0.57 0.33 (0.13–0.86) 0.02
Previous drug overdose
No 429 (88.3) 161 (88.0) 1 1
Yes 57 (11.7) 22 (12.0) 2.07 (0.51–8.33) 0.31 2.30 (0.55–9.57) 0.25
History of drug injection
No 244 (51.6) 88 (50.6) 1 1
Yes 229 (48.4) 86 (49.4) 1.99 (0.75–5.30) 0.17 3.98 (1.39–11.37) 0.01
Age at first drug usea 18 (17–21) 0.92 (0.83–1.02) 0.12 0.86 (0.75–0.98) 0.03
Methadone dose >60 mg
No 305 (66.7) 164 (92.7) 1 1
Yes 152 (33.3) 84 (47.5) 1.37 (0.51–3.68) 0.54 0.82 (0.29–2.32) 0.71
Perceiving methadone dose to be too low
No 265 (94.3) 151 (96.8) 1 1
Yes 16 (5.7) 13 (8.3) 1.23 (0.08–18.09) 0.88 6.06 (0.68–53.78) 0.11
Depressive symptomsb
No 310 (68.3) 142 (81.6) 1 1
Yes 144 (31.7) 86 (49.4) 2.12 (0.88–5.11) 0.09 4.32 (1.71–10.92) 0.002
Risk of suicidec
No 279 (72.7) 133 (81.1) 1 1
Yes 105 (27.3) 69 (42.1) 1.62 (0.68–3.86) 0.28 3.93 (1.59–9.76) 0.003
ADHD symptoms
No 304 (79.0) 148 (89.7) 1 1
Yes 81 (21.0) 59 (35.8) 1.48 (0.55–4.01) 0.44 6.17 (2.34–16.22) <0.001
At least 1 withdrawal symptom
No 296 (72.0) 148 (87.1) 1 1
Yes 115 (28.0) 103 (60.6) 1.42 (0.52–3.89) 0.50 1.51 (0.52–4.38) 0.45
Alcohol dependenced
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contingency management and cognitive behavioral ther-
apy [6, 44, 45]. However, findings regarding the efficacy
of psychotherapy for cocaine abuse in MMT patients are
mixed. For example, in one article, counseling therapy for
cocaine users in a population of methadone-maintained
patients was not effective [46], while another article
showed that CBT may indeed have a positive impact [6].
More generally, long-term studies highlight the weakness
in providing only CBT [47].
We also found that depressive symptoms were associ-
ated with cocaine use. The relationship between cocaine
use and depression is complex, and the causality direc-
tion is unclear. It is known that cocaine-dependent indi-
viduals are more likely to have depressive symptoms,
depression perhaps being a preliminary condition for co-
caine dependence [48]. However, one recent study has
also highlighted that depression may also be a conse-
quence of cocaine use [49]. In any case, depression
should be diagnosed and treated in a timely fashion in
order to reduce its negative impact on the effectiveness
of OMT. Although it has been shown that certain anti-
depressants are not effective in reducing cocaine use in
cocaine and opioid co-dependent patients [50, 51], some
studies have demonstrated that access to adequate care
for depression in cocaine-dependent patients may lead
to decreased cocaine use [52, 53].
In addition, persistent opiate injection during metha-
done maintenance (i.e., non-response to opioid depend-
ence treatment) was associated with persistent (both
occasional and regular) cocaine use. This suggests that
methadone treatment (at the prescribed dosages) may be
an inadequate opioid dependence treatment; and that
for such patients, methadone treatment has a negligible
impact on cocaine use. In addition, two associations with
regular cocaine use found in the univariate analyses may
help us better understand the relationship between
heroin injection and regular cocaine use: reporting with-
drawal symptoms and a tendency to perceive methadone
Table 2 Factors associated with cocaine use: logistic mixed model adjusted for follow-up visit (Continued)
No 274 (88.1) 157 (91.3) 1 1
Yes 37 (11.9) 27 (15.7) 3.08 (0.88–10.80) 0.08 4.10 (1.15–14.61) 0.03
Opiate injectione
No 414 (91.4) 164 (95.3) 1 1
Yes 39 (8.6) 24 (13.8) 6.06 (1.29–28.44) 0.02 12.42 (2.72–56.61) 0.001
Univariate analyses: N = 486 visits; 183 persons
aIn years
bCES-D score >17 for males and >23 for females
cBeck ≥9
dAUDIT score ≥13
eDuring the previous 4 weeks
Table 3 Factors independently associated with occasional and regular cocaine use: logistic mixed model
Occasional cocaine use vs no use Regular cocaine use vs no use
ORa [95 % CI] p ORa [95 % CI] p
Follow-up
M0 1 1
M6 0.48 [0.18–1.27] 0.14 0.77 [0.26–2.26] 0.63
M12 0.33 [0.12–0.95] 0.04 0.38 [0.11–1.32] 0.13
Depressive symptomsb
No 1
Yes 2.41 [0.92–6.31] 0.07 3.49 [1.21–10.04] 0.02
ADHD symptoms
No 1
Yes 1.40 [0.47–4.18] 0.55 5.23 [1.74–15.71] 0.003
Opiate injectiona
No
Yes 5.73 [1.26–25.99] 0.02 8.98 [1.87–43.22] 0.01
Multivariate analyses: N = 353 visits; 156 persons
aDuring the previous 4 weeks
bCES-D score >17 for males and >23 for females
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dose as too low were both associated with regular co-
caine use (but not occasional cocaine use). This may also
suggest that cocaine has a pharmacokinetic impact on
methadone which decreases the effect of the latter
[12]. To conclude, persistent heroin injection during
MMT may be explained by underdosing of metha-
done [54] and/or inappropriate treatment for opioid
dependence [55].
Finally, it is interesting to note that a longer time on
methadone (measured in terms of each follow-up visit)
was associated with reduced occasional cocaine use but
no such association was seen for regular cocaine use.
This suggests that higher levels of cocaine use in
methadone-maintained patients may not be influenced
by medical follow-up for opioid dependence.
Some limitations of this study have to be acknowl-
edged. First, we did not identify cocaine dependence in
our sample. This data would have been interesting to
analyze as cocaine-dependent patients may have been
those who did not respond to MMT. The role of cocaine
use in ADHD should be investigated more thoroughly,
as the ASRS-v1.1 recently reported low specificity in the
detection of ADHD among populations with substance
use disorders [56]. The second limitation is that the val-
idity of self-reported behaviors is often questioned due
to the risk of underreporting linked to social desirability
bias. However, this effect modifies OR estimates in a
conservative manner. Furthermore, the reliability of self-
reports based on using the Opiate Treatment Index
(OTI) treatment questionnaire in drug-using populations
has already been demonstrated [57].
Conclusions
As suggested by previous findings, in our study, time
on MMT had a positive impact on occasional cocaine
users. However, regular cocaine use was not influ-
enced by MMT duration but was associated with psy-
chiatric comorbidities (ADHD and depression) and
more severe addictive profiles (opioid injection). Early
screening of these disorders and prompt tailored
pharmacological and behavioral interventions have the
potential to reduce cocaine use and to improve
response to MMT.
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